NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians navigate complex treatment decisions more confidently.
PanTracer Tissue evaluates over 500 cancer-related genes and aligns with clinical guidelines, covering key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment. Results may be delivered in as little as 8 days, enabling physicians to rapidly initiate treatment strategies. Minimal specimen requirements make it suitable for a wide range of tumor types and practice settings. The assay builds on the company's tissue-based CGP platform, previously known as NeoComprehensive ® Solid Tumor.
The addition of PanTracer Tissue + HRD offers enhanced tumor profiling by incorporating homologous recombination deficiency analysis into a single, guideline-aligned test for ovarian cancer. The PanTracer Tissue + HRD offering includes BRCA mutation status and a genomic instability score—critical biomarkers that can help guide the use of PARP inhibitors and other therapies targeting DNA repair pathways. The combined approach streamlines ordering and can shorten time to actionable results by capturing a broader range of clinically relevant genomic alterations, gene fusions, and DNA repair deficiencies.
'With PanTracer Tissue and PanTracer Tissue + HRD we're unlocking a more complete genomic view from a single sample, giving physicians clearer answers, sooner,' said Warren Stone, President and Chief Operating Officer at NeoGenomics. 'With the addition of PanTracer Tissue + HRD, we are expanding our portfolio to address the unmet need for ovarian cancer therapy selection with the objective of improving patient care.'
PanTracer Tissue and PanTracer Tissue + HRD are part of NeoGenomics' broader portfolio of precision oncology solutions designed to improve patient outcomes through high-quality, guideline-aligned testing. Revealed at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the continually expanding PanTracer portfolio reflects the company's dedicated focus on advancing diagnostic tools that support more informed, personalized care.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'can,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the potential impact of PanTracer™ Tissue, including the use of HRD testing, in oncology treatment and clinical trial enrollment. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the extent of use by oncologists and biopharma companies of PanTracer™ Tissue + HRD, the speed and utility of the results generated, and the risks identified under the heading 'Risk Factors' contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the 'Investors' section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250630394462/en/
CONTACT: Investor Contact
Kendra Webster
[email protected] Contact
Andrea Sampson
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA FLORIDA
INDUSTRY KEYWORD: RESEARCH MEDICAL DEVICES GENETICS CLINICAL TRIALS BIOTECHNOLOGY RADIOLOGY HEALTH SCIENCE ONCOLOGY
SOURCE: NeoGenomics, Inc.
Copyright Business Wire 2025.
PUB: 06/30/2025 07:05 AM/DISC: 06/30/2025 07:05 AM
http://www.businesswire.com/news/home/20250630394462/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Trump official criticizes Fed chief Powell as Trump takes aim over interest rates
A top Trump administration official accused Federal Reserve Chair Jerome Powell of leading an "ostentatious" office renovation project that may be "violating the law," a new broadside against the central bank chief as President Trump tangles with him over interest rates. "The President is extremely troubled by your management of the Federal Reserve System," Office of Management and Budget Chair Russell Vought wrote in a July 10 letter. The letter came after months of criticism from Mr. Trump over the Fed's decision not to slash interest rates. Economists say lowering rates may accelerate economic growth, but it also runs the risk of causing inflation to spike. That has led the Fed's interest rate-setting committee — which Powell chairs — to keep rates steady so far this year after cutting rates slightly last year. Mr. Trump has called on Powell to resign from his post, and last month, the president called Powell a "numbskull" over his interest rate decisions and said "maybe" he'll try to fire Powell — though federal law states the Fed chair can only be fired "for cause," which typically refers to firings due to specific misconduct or performance issues. In the past, Mr. Trump had said he doesn't plan on trying to fire Powell, whose term as Fed chair ends next year. Vought's letter took aim at Powell and the central bank over its yearslong office renovation project in Washington, D.C. The letter said plans for the project "called for rooftop terrace gardens, VIP private dining rooms and elevators, water features, premium marble, and much more." Vought also asked whether the Fed has made changes to its plans without seeking approval from a government commission that oversees D.C.-area federal building projects. In testimony to the Senate last month, Powell called some descriptions of the renovation project "misleading and inaccurate." He told lawmakers there isn't any new marble aside from what's necessary to replace broken old marble, and said there are no "special elevators," new water features or rooftop gardens. "All of the sort of inflammatory things that the media carried are either not in the current plan or just inaccurate," Powell said. Vought's letter argued that comment to the Senate "appears to reveal that the project is out of compliance with the approved plan," suggesting the Fed may have run afoul of a law requiring D.C.-area projects be approved by the National Capital Planning Commission. In a post on X, the Office of Management and Budget alleged Powell "slipped up and revealed he violating the law." The Fed's renovation plans were reviewed by the commission several years ago. Powell defended the Fed's handling of the project in a letter Thursday responding to Vought, saying the Fed has "taken great care to ensure the project is carefully overseen." He also said the project has been "subject to budget approval" by board members annually. The Fed chair said the Fed generally isn't subject to the National Capital Planning Commission's approval, but it did work with the agency "voluntarily" in 2020 and 2021. Since then, Powell said, the central bank has only "made a small number of design changes to scale back or eliminate certain elements," so no further review by the commission is needed. The Fed typically operates with a much higher degree of independence than most other government institutions. Federal law gives the Fed the power to make decisions about acquiring and remodeling buildings in Washington to serve as its office spaces. The Fed has previously acknowledged that the price tag for its office renovations had jumped due to "significant increases in raw materials costs," along with higher labor costs. On its website, the Fed says the two headquarters buildings that are getting overhauled "have not been comprehensively renovated since their construction in the 1930s." The central bank said there are no private elevators or new VIP dining rooms — instead, the project will refurbish old elevators and conference rooms, including ones that are sometimes "used for mealtime meetings." It also said plans for new water features were scrapped, though existing fountains will be repaired, and the garden terrace is actually a "ground-level front lawn." On July 2, Bill Pulte, the Trump-nominated head of the Federal Housing Finance Agency, accused Powell of "deceptive" testimony to the Senate about the office project. When asked about the allegation in a recent Cabinet meeting, Mr. Trump said: "Then he [Powell] should resign immediately. We should get somebody in it that's going to lower interest rates." Son of man who was violently detained by ICE reacts after release Mike Johnson breaks from Trump, calls on DOJ to release Epstein files 7.3 magnitude earthquake hits southern Alaska Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Watch These Johnson & Johnson Price Levels After Stock's Post-Earnings Pop
Key Takeaways Johnson & Johnson shares fell slightly Thursday after soaring yesterday amid investor optimism about the company's better-than-expected earnings and full-year outlook. The stock rallied above key moving averages and a symmetrical triangle in Wednesday's trading session, though it remains in a long-term trading range. Investors should watch crucial overhead areas on J&J's chart around $168 and $180, while also monitoring major support levels near $155 and $ & Johnson (JNJ) shares lost ground Thursday after soaring yesterday amid investor optimism about the company's better-than-expected earnings and full-year outlook. The healthcare giant also slashed its tariff cost forecast, saying it now expects about $200 million in import levy-related costs this year, down from its prior projection of $400 million. The outlook soothed investors' concerns about what impact Washington's trade policies would have on the company after President Donald Trump recently said that pharmaceutical tariffs could be as high as 200%. The drugmaker said its portfolio and pipeline position it for elevated growth in the second half of the year, adding that it anticipates approvals and submissions across a range of therapeutic areas. J&J shares fell 1% to close today's session at around $163, after surging 6% on Wednesday to pace Dow Jones Industrial Average advancers. The stock has risen 13% since the start of the year, outpacing the Dow's gain of less than 5%. Below, we break down the technicals on J&J's weekly chart and identify price levels worth watching out for. Close Above Key Moving Averages Although the 50-week moving average (MA) crossed below the 200-week MA in late 2023 to form an ominous death cross, J&J shares have remained mostly rangebound since that time. However, more recently, the price rallied above both of these moving averages and a symmetrical triangle in Wednesday's trading session. While the relative strength index confirms a positive shift in momentum, yesterday's jump occurred on lackluster volume, indicating that larger market participants may remain on the sidelines. Let's point out crucial overhead areas on J&J's chart to watch and also identify a couple of major support levels worth monitoring during future retracements. Overhead Areas to Watch Upon further buying, Investors should monitor how the price responds to the $168 area. This level may provide overhead resistance near prominent peaks in September last year and March this year that touch a trendline extending back to February 2021. A decisive volume-backed breakout above this area could trigger a rally toward $180. Investors who have accumulated shares at lower prices may look for exit points in this location near notable peaks that formed in the chart in August 2021 and December 2022, both of which lie just below the stock's all-time high. Support Levels Worth Monitoring During future retracements in the stock, investors should monitor the $155 level. This area, which sits just below the 50-week MA and the symmetrical triangle's top trendline, may encounter support near a horizontal line that links a range of corresponding trading activity on the chart stretching back to the April 2020 peak. Finally, a deeper pullback in J&J shares could see the price revisit lower support around $145. Investors may look for buying opportunities in this region near several troughs that developed on the chart between October 2023 and January this year, a level that marks the lower level of the stock's trading range over that period. The comments, opinions, and analyses expressed on Investopedia are for informational purposes only. Read our warranty and liability disclaimer for more info. As of the date this article was written, the author does not own any of the above securities. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Judge denies 23XI Racing and Front Row Motorsports' request to race with charters
CHARLOTTE, N.C. (AP) — A federal judge on Thursday rejected a request from 23XI Racing and Front Row Motorsports to continue racing with charters while they battle NASCAR in court, meaning their six cars will race as open entries this weekend at Dover, next week at Indianapolis and perhaps longer than that in a move the teams say would put them at risk of going out of business. U.S. District Judge Kenneth Bell denied the teams' bid for a temporary restraining order, saying they will make races over the next couple of weeks and they won't lose their drivers or sponsors before his decision on a preliminary injunction. Bell left open the possibility of reconsidering his decision if things change over the next two weeks. After this weekend, the cars affected may need to qualify on speed if 41 entries are listed — a possibility now that starting spots have opened. 23XI, which is co-owned by retired NBA great Michael Jordan, and FRM filed their federal suit against NASCAR last year after they were the only two organizations out of 15 to reject NASCAR's extension offer on charters. The case has a Dec. 1 trial date, but the two teams are fighting to be recognized as chartered for the current season, which has 16 races left. A charter guarantees one of the 40 spots in the field each week, but also a base amount of money paid out each week. Jordan and FRM owner Bob Jenkins won an injunction to recognize 23XI and FRM as chartered for the season, but the ruling was overturned on appeal earlier this month, sending the case back to Bell. Three-time Daytona 500 winner Denny Hamlin co-owns 23XI with Jordan and said they were prepared to send Tyler Reddick, Bubba Wallace and Riley Herbst to the track each week as open teams. They sought the restraining order Monday, claiming that through discovery they learned NASCAR planned to immediately begin the process of selling the six charters which would put 'plaintiffs in irreparable jeopardy of never getting their charters back and going out of business.' 'This is a fair and significant fear; however, NASCAR has agreed that it 'will not sell any charters before the court can rule on plaintiffs' motion for preliminary injunction,'' Ball wrote. 'Similarly, plaintiffs worry that denying them guaranteed entry into the field for upcoming races could adversely impact their competitive standing, including their ability to earn a spot in the playoffs. Again, a legitimate, potentially irreparable harm. Yet, akin to the sale of charters, NASCAR represents to the court that all of plaintiffs' cars will qualify (if they choose to race) for the races in Dover and Indianapolis that will take place during the next 14 days.' Making the field won't be an issue this weekend at Dover as fewer than the maximum 40 cars are entered. But should 41 cars show up anywhere this season, someone slow will be sent home and that means lost revenue and a lost chance to win points in the standings. Reddick was last year's regular season champion and raced for the Cup Series championship in the season finale. But none of the six drivers affected by the court ruling are locked into this year's playoffs. ___ AP auto racing: Jenna Fryer, The Associated Press
